Neuronetics ( (STIM) ) has released its Q3 earnings. Here is a breakdown of the information Neuronetics presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neuronetics, Inc. is a medical technology and healthcare company focused on providing advanced neurohealth therapies, including the NeuroStar Advanced Therapy System, to treat mental health disorders such as major depressive disorder.
In its third quarter of 2025 earnings report, Neuronetics announced a significant revenue increase, driven by its Greenbrook clinic acquisition, and a strategic transition plan for its CEO. The company reported a total revenue of $37.3 million, marking a 101% increase from the same period in 2024.
Key financial highlights include a 25% growth in U.S. Greenbrook clinic revenue on an adjusted pro forma basis and a strengthened balance sheet with $34.5 million in total cash. Despite a decrease in gross margin to 45.9% due to the inclusion of Greenbrook’s clinic business, the company showed improved cash management with only $0.8 million used in operations. Additionally, Neuronetics secured $10 million in funding and expanded Medicaid coverage for its TMS therapy in New York State.
Looking forward, Neuronetics is optimistic about its growth trajectory, expecting total worldwide revenue between $147 million and $150 million for the full year 2025. The company aims to achieve positive cash flow from operations by the end of the year, reflecting confidence in its strategic initiatives and operational efficiencies.